Indium In-111 is under investigation in clinical trial NCT00493454 (Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas). Indium In-111 is a radioisotope with a physical half-life of 2.83 days, used to label agents for diagnosis, disease progression and treatment. (NCI). It is grouped under the following drug class(es): Radiopharmaceuticals. Its therapeutic use is listed as diagnostic agents. The directory classifies it as a commercial API with a mineral/inorganic source/manufacturing origin. Other names for this substance include Indium In-111 and 111In radioisotope. Its PubChem CID is 5462099.
Indium-111
| CAS No | 15750-15-9 |
|---|---|
| Molecular Formula | In |
| Molecular Weight | 110.91 g/mol |
| Synonyms | indium-111 |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Indium In-111 is under investigation in clinical trial NCT00493454 (Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas). 83 days, used to label agents for diagnosis, disease progression and treatment.
The listed CAS number is 15750-15-9.
The listed molecular formula is In.
The listed molecular weight is 110.91 g/mol.
indium-111.
The source lists Indium In-111 and 111In radioisotope.